EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes

April Gregson, Shakeel Mowlaboccus, Sruthi Mamoottil Sudeep, Sophia Rizzo, Jignasa Purani, Elena Martinez, Geoffrey Coombs, Indy Sandaradura iD, Genevieve McKew iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von April Gregson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Ceftriaxone, Enterococcus faecalis, Anti-Bacterial Agents, Gram-Positive Bacterial Infections. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ioMérieux Australia, Department of Infectious Diseases and Microbiology, Concord Hospital, School of Medical, Molecular and Forensic Sciences, Murdoch University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Benzylpenicillin with ceftriaxone is used for outpatient antimicrobial therapy of Enterococcus faecalis infective endocarditis (EFIE) due to poor stability of aminopenicillins. The aim was to correlate the impact of benzylpenicillin-ceftriaxone synergy on EFIE treated with benzylpenicillin-ceftriaxone, and investigate whether simpler phenotypic methods can predict synergy.

Methods

Clinical outcomes of a retrospective cohort of EFIE patients were correlated with treatment and synergy. Isolates were assessed for synergy using the checkerboard method, compared with double disc diffusion (DDD) and layered and crossed gradient diffusion strip (GDS) tests, with sensitivity and specificity of these methods calculated.

Results

Thirty-eight episodes of EFIE in 34 patients were included; the majority received benzylpenicillin-ceftriaxone alone (n = 16) or in sequence (n = 12; any benzylpenicillin-ceftriaxone n = 28), and 10 received other regimens. There was no statistical difference between any benzylpenicillin-ceftriaxone versus other therapies on outcomes, nor between benzylpenicillin-ceftriaxone synergy and outcome. GDS was an unreliable predictor of checkerboard synergy; DDD was reasonable. Five isolates lacked benzylpenicillin-ceftriaxone synergy (one also lacking ampicillin-ceftriaxone synergy); these all had high-level ceftriaxone resistance [zone diameter 6 mm, or broth microdilution (BMD) MIC >512 mg/L]. Most isolates from relapse cases developed reduced zone diameters to ceftriaxone. Two isolates lacking synergy had the same mutation near the ceftriaxone response regulator (CroR) binding site in the pbp4 promoter region.

Conclusions

Ceftriaxone susceptibility, either MIC <512 mg/L by BMD or disc zone diameter >6 mm, is the best predictor of ampicillin-ceftriaxone and particularly benzylpenicillin-ceftriaxone synergy in E. faecalis. There was no clear relationship between the absence of benzylpenicillin-ceftriaxone synergy and outcome in this highly comorbid cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftriaxoneEnterococcus faecalisAnti-Bacterial AgentsGram-Positive Bacterial InfectionsDrug SynergismEndocarditis, Bacterialbeta-LactamsHumansMaleFemaleRetrospective StudiesMicrobial Sensitivity TestsTreatment OutcomeMiddle AgedAgedAdultSensitivity and SpecificityAged, 80 and over

Substanzen

CeftriaxoneAnti-Bacterial Agentsbeta-Lactams

Autor:innen und Institutionen

  • Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • School of Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, WA, Australia.
  • Department of Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, Murdoch, WA, Australia.
  • Concord Microbiology, Concord Repatriation and General Hospital, NSW Health Pathology, Sydney, NSW, Australia.
  • Antimicrobial Resistance Laboratory, Centre for Infectious Diseases and Microbiology, Institute for Clinical and Pathological Sciences, Westmead Hospital, NSW Health Pathology, Sydney, NSW, Australia.
  • School of Medical Sciences, Faculty of Medicine and Sciences, University of Sydney, Sydney, NSW, Australia.

ORCID-Profile: Indy Sandaradura, Genevieve McKew

Förderung

  • ioMérieux Australia
  • Department of Infectious Diseases and Microbiology, Concord Hospital
  • School of Medical, Molecular and Forensic Sciences, Murdoch University

Zitieren

APA

Gregson, A., Mowlaboccus, S., Sudeep, S. M., Rizzo, S., Purani, J., Martinez, E., Coombs, G., Sandaradura, I., & McKew, G. (2025). Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf377

Vancouver

Gregson A, Mowlaboccus S, Sudeep SM, Rizzo S, Purani J, Martinez E, et al. Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf377

BibTeX
@article{Gregson2025,
  author = {Gregson, April and Mowlaboccus, Shakeel and Sudeep, Sruthi Mamoottil and Rizzo, Sophia and Purani, Jignasa and Martinez, Elena and Coombs, Geoffrey and Sandaradura, Indy and McKew, Genevieve},
  title = {Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf377}
}
Kostenlos starten →